University of Oulu

Hirvonen, M.K., Lietzén, N., Moulder, R. et al. Serum APOC1 levels are decreased in young autoantibody positive children who rapidly progress to type 1 diabetes. Sci Rep 13, 15941 (2023).

Serum APOC1 levels are decreased in young autoantibody positive children who rapidly progress to type 1 diabetes

Saved in:
Author: Hirvonen, M. Karoliina1,2; Lietzén, Niina1; Moulder, Robert1,2;
Organizations: 1Turku Bioscience Centre, University of Turku and Åbo Akademi University, Turku, Finland
2InFLAMES Research Flagship Center, University of Turku, Turku, Finland
3Department of Biochemistry and Molecular Biology, University of Southern Denmark, Odense, Denmark
4Department of Pediatrics, University of Turku and Turku University Hospital, Turku, Finland
5Institute of Biomedicine, Research Centre for Integrative Physiology and Pharmacology, and Centre for Population Health Research, University of Turku, Turku, Finland
6School of Medical Sciences, Örebro University, Örebro, Sweden
7Immunogenetics Laboratory, University of Turku, Turku, Finland
8Department of Pediatrics, Research Unit of Clinical Medicine, Medical Research Center, University of Oulu, Oulu, Finland
9Department for Children and Adolescents, Medical Research Center, Oulu University Hospital, Oulu, Finland
10Faculty of Medicine and Health Technology, Tampere University, Tampere, Finland
11Fimlab Laboratories, Tampere, Finland
12Department of Computer Science, Aalto University School of Science, Aalto, Finland
13Pediatric Research Center, New Children’s Hospital, Helsinki University Hospital, Helsinki, Finland
14Research Program for Clinical and Molecular Metabolism, Faculty of Medicine, University of Helsinki, Helsinki, Finland
15Department of Pediatrics, Tampere University Hospital, Tampere, Finland
16Institute of Biomedicine, University of Turku, Turku, Finland
Format: article
Version: published version
Access: open
Online Access: PDF Full Text (PDF, 1.9 MB)
Persistent link:
Language: English
Published: Springer Nature, 2023
Publish Date: 2023-10-13


Better understanding of the early events in the development of type 1 diabetes is needed to improve prediction and monitoring of the disease progression during the substantially heterogeneous presymptomatic period of the beta cell damaging process. To address this concern, we used mass spectrometry-based proteomics to analyse longitudinal pre-onset plasma sample series from children positive for multiple islet autoantibodies who had rapidly progressed to type 1 diabetes before 4 years of age (n = 10) and compared these with similar measurements from matched children who were either positive for a single autoantibody (n = 10) or autoantibody negative (n = 10). Following statistical analysis of the longitudinal data, targeted serum proteomics was used to verify 11 proteins putatively associated with the disease development in a similar yet independent and larger cohort of children who progressed to the disease within 5 years of age (n = 31) and matched autoantibody negative children (n = 31). These data reiterated extensive age-related trends for protein levels in young children. Further, these analyses demonstrated that the serum levels of two peptides unique for apolipoprotein C1 (APOC1) were decreased after the appearance of the first islet autoantibody and remained relatively less abundant in children who progressed to type 1 diabetes, in comparison to autoantibody negative children.

see all

Series: Scientific reports
ISSN: 2045-2322
ISSN-E: 2045-2322
ISSN-L: 2045-2322
Volume: 13
Issue: 1
Article number: 15941
DOI: 10.1038/s41598-023-43039-4
Type of Publication: A1 Journal article – refereed
Field of Science: 3121 General medicine, internal medicine and other clinical medicine
Funding: This study was supported by the InFLAMES Flagship Programme of the Academy of Finland (decision number: 337530) and JDRF Grant 1-SRA-2017-357-Q-R to M.O., M.K. and R.L. M.K.H. was supported by Turku Doctoral Programme of Molecular Medicine (TuDMM) and grants by Turku University Foundation, Finnish Cultural Foundation (Grant 85182227), Kyllikki and Uolevi Lehikoinen Foundation and Finnish Diabetes Research Foundation. N.L. received funding from the Academy of Finland (Grant 287423). L.C. received funding from the Academy of Finland (Grant 335858). R.L. received funding from the Academy of Finland (Grants 292335, 294337, 31444, 319280, 329277, 331790), Business Finland and grants from the Sigrid Jusélius Foundation (SJF), Jane and Aatos Erkko Foundation, Novo Nordisk Foundation, Finnish Diabetes Foundation and the Finnish Cancer Foundation. R.L., H.L., M.K., M.O. and J.T. were supported by the Academy of Finland, Centre of Excellence in Molecular Systems Immunology and Physiology Research (2012–2017) Grant 250114 and Grant 292482. J.T. was funded by EFSD, Pediatric Research Foundation, and Turku University Hospital Special Governmental Grants. R.V. received funding for the DIPP study from the JDRF (Grants 1-SRA-2016-342-M-R and 1-SRA-2019-732-M-B), the Academy of Finland (Grant 308067) and the Finnish Diabetes Foundation. H.H. received a grant from the Academy of Finland (Grant 288671) and Novo Nordisk Foundation. The DIPP Study was also supported by Special Research Funds for University Hospitals in Finland. Our research is as well supported by University of Turku Graduate School (UTUGS) and Biocenter Finland.
Academy of Finland Grant Number: 308067
Detailed Information: 308067 (Academy of Finland Funding decision)
Copyright information: © The Author(s) 2023. This article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons licence, and indicate if changes were made. The images or other third party material in this article are included in the article's Creative Commons licence, unless indicated otherwise in a credit line to the material. If material is not included in the article's Creative Commons licence and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this licence, visit